Intellia Therapeutics Inc
NTLA11.620USD
+0.130+1.13%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.20BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Intellia Therapeutics Inc Unternehmen
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Unternehmensinformationen
BörsenkürzelNTLA
Name des UnternehmensIntellia Therapeutics Inc
IPO-datumMay 06, 2016
CEODr. John M. Leonard, M.D.
Anzahl der mitarbeiter403
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse40 Erie St Ste 130
StadtCAMBRIDGE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02139-4254
Telefon18572856200
Websitehttps://www.intelliatx.com/
BörsenkürzelNTLA
IPO-datumMay 06, 2016
CEODr. John M. Leonard, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
19.97K
+66.85%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
4.52K
-35.64%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Umsatzaufteilung
FY2025Q1
FY2024
FY2023
FY2022
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
16.63M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 18
Aktualisiert: Fri, Jul 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.59%
Investment Advisor/Hedge Fund
20.47%
Hedge Fund
14.23%
Research Firm
6.53%
Corporation
3.57%
Individual Investor
1.49%
Bank and Trust
0.78%
Pension Fund
0.32%
Private Equity
0.22%
Other
1.79%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
699
101.80M
98.27%
-16.60M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
2023Q1
811
82.36M
94.28%
-4.97M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
ARK Investment Management LLC
13.01M
12.56%
+474.63K
+3.79%
Mar 31, 2025
The Vanguard Group, Inc.
10.73M
10.36%
+561.98K
+5.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
8.12%
-411.95K
-4.67%
Mar 31, 2025
State Street Global Advisors (US)
4.51M
4.35%
-695.44K
-13.36%
Mar 31, 2025
Two Sigma Investments, LP
3.98M
3.84%
+120.05K
+3.11%
Mar 31, 2025
Capital International Investors
3.78M
3.65%
+3.78M
--
Mar 31, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.57%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.76M
2.66%
+263.50K
+10.56%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.83M
2.73%
-167.30K
-5.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.48M
2.39%
+90.93K
+3.81%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ARK Genomic Revolution ETF
2.65%
WisdomTree BioRevolution Fund
2.48%
ARK Innovation ETF
1.25%
Global X Genomics & Biotechnology ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
Tema Neuroscience and Mental Health ETF
0.54%
SPDR S&P Biotech ETF
0.31%
Tema Heart & Health ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Avantis US Small Cap Equity ETF
0.12%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil2.65%
WisdomTree BioRevolution Fund
Anteil2.48%
ARK Innovation ETF
Anteil1.25%
Global X Genomics & Biotechnology ETF
Anteil1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.01%
Tema Neuroscience and Mental Health ETF
Anteil0.54%
SPDR S&P Biotech ETF
Anteil0.31%
Tema Heart & Health ETF
Anteil0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.17%
Avantis US Small Cap Equity ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
